Shares of Tiziana Life Sciences PLC (LON:TILS – Get Free Report) passed below its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of GBX 58.50 ($0.72) and traded as low as GBX 45 ($0.55). Tiziana Life Sciences shares last traded at GBX 58.50 ($0.72), with a volume of 297,127 shares changing hands.
Tiziana Life Sciences Stock Up 8.3 %
The firm has a market capitalization of £113.85 million and a price-to-earnings ratio of -3.59. The company has a debt-to-equity ratio of 2.36, a quick ratio of 6.41 and a current ratio of 6.54. The business’s 50 day moving average is GBX 58.50 and its 200-day moving average is GBX 58.50.
Tiziana Life Sciences Company Profile
Tiziana Life Sciences Plc, a clinical stage biotechnology company, focuses on the discovery and development of molecules and related diagnostics to treat diseases in oncology and immunology in the United Kingdom. Its product pipeline includes Foralumab (TZLS-401), a human anti-CD3 monclonal antibody for the treatment of autoimmune and inflammatory diseases, such as GvHD, ulcerative colitis, Crohn's disease, multiple sclerosis, type-1 diabetes, inflammatory bowel diseases, psoriasis, and rheumatoid arthritis; and Milciclib (TZLS-201), which is an orally bioavailable, small molecule inhibitor of cyclin-dependent kinases and Src family kinases for the treatment of hepatocellular carcinoma.
- Five stocks we like better than Tiziana Life Sciences
- NYSE Stocks Give Investors a Variety of Quality Options
- 3 large caps with red hot RSIs with upside
- What is a Stock Market Index and How Do You Use Them?
- Johnson Controls International: Nothing but upside for investors
- Short Selling: How to Short a Stock
- Unity Software’s resilient rebound post-earnings setback
Receive News & Ratings for Tiziana Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tiziana Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.